钠-葡萄糖共转运蛋白2抑制剂对糖尿病患者心血管系统作用的研究进展

Progress in research on the effect of sodium-glucose co-transporter 2 inhibitors on cardiovascular system in diabetic patients

全球2型糖尿病的患者数已达约4. 25亿例,预计在2045年将会有将近7亿例罹患糖尿病,其中60%的2型糖尿病患者死于心血管疾病。2008年,FDA要求所有降糖新药申报其临床试验中的心血管事件。目前,除二甲双胍、利拉鲁肽和恩格列净外,大多数抗糖尿病药物对心血管表现出中性或负性的作用。越来越多的多中心随机对照试验和真实世界研究报道了新型降糖药钠-葡萄糖共转运蛋白2抑制剂对糖尿病患者的心血管保护作用。本文将对钠-葡萄糖共转运蛋白2抑制剂对糖尿病患者心血管系统作用的相关研究进行综述,并对其保护作用可能的机制进行总结。

The number of patients with type 2 diabetes mellitus in the world has reached approximately 425 million. It is estimated that nearly 700 million people will suffer from diabetes in 2045,and among them 60% of type 2 diabetes mellitus patients will die of cardiovascular disease. In 2008,the FDA required all new anti-diabetic drugs to declare cardiovascular events in their clinical trials. Currently,with the exception of metformin,liraglutide and engleglifloxacin,most anti-diabetic drugs have shown neutral or negative effect on the cardiovascular system. A growing number of multicenter randomized controlled trials and real-world studies have been reported that there is cardiovascular protection on diabetic patients who have used novel anti-diabetic drugs sodium-glucose co-transporter2 inhibitors. This article reviewed studies on the role of sodium-glucose co-transporter 2 inhibitors in the cardiovascular system of diabetic patients and summarized the possible mechanisms of their protective effects.